Maverick Capital’s AstraZeneca AZN Stock Holding History

Maverick Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-11,185	Closed	-$1.34M	–	343
2021 Q3	$1.34M	Sell	11,185 -885	-7%	-$103K	0.01%	229
2021 Q2	$1.45M	Sell	12,070 -15,095	-56%	-$1.66M	0.01%	205
2021 Q1	$2.7M	Buy	27,165 +20,655	+317%	+$2.08M	0.02%	125
2020 Q4	$651K	Buy	+6,510	New	+$690K	0.01%	314

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Maverick Capital's AZN Position: Q4 2021 in Review

Maverick Capital sold out of AstraZeneca (AZN) in Q4 2021, closing a stake of 11,185 shares — an estimated $1.34M sold.

Maverick Capital first reported a position in AZN in Q4 2020 and held it in 4 quarters. The position peaked at $2.7M in Q1 2021. 949 funds tracked by Wall St. Rank hold AZN as of Q4 2021.

Maverick Capital reported no remaining AstraZeneca position as of Q4 2021 after selling out during the quarter.
Maverick Capital sold 11,185 AstraZeneca shares in Q4 2021, an estimated $1.34M.
Maverick Capital first reported a position in AstraZeneca in Q4 2020 and held it in 4 quarters.
Maverick Capital's AstraZeneca position peaked at $2.7M in Q1 2021.
949 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2021.

Based on Maverick Capital's 13F filing for Q4 2021, filed 14 Feb 2022.